Navigation Links
Oral COTI-2 is effective in a second animal model of human pancreatic cancer
Date:1/20/2010

London, Ontario (January 20, 2010): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT)announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.

This most recent study was designed to determine first, the effectiveness of oral COTI-2 as a single agent, second, the effectiveness of COTI-2 in combination with Abraxane, a standard first line therapy for advanced pancreatic cancer, and third, the toxicity of chronically administered oral COTI-2 as a single agent and in combination with Abraxane in an animal model of human pancreatic cancer (PANC-1). The following results provide strong evidence for the continued development of COTI-2 in combination with conventional single agent therapy for the treatment of pancreatic cancer:

  • COTI-2 is effective as a single agent in an animal model of human pancreatic cancer.

  • COTI-2 plus Abraxane was significantly more effective than Abraxane as a single agent and this result was observed by day 28 of the study.

  • The combination treatment group receiving COTI-2 plus Abraxane responded earlier than the Abraxane alone.

  • Complete tumor regressions were observed more frequently in the combination treatment groups than with single agent Abraxane.

  • At the conclusion of the study mean tumor volumes in the Abraxane only treated animals were trending higher while mean tumor volumes in the combination treatment group were trending lower.

  • Chronic oral treatment with COTI-2 as a single agent or in combination with Abraxane was well tolerated with no treatment deaths or observable toxicity over the duration of the study. '/>"/>

Contact: Michael Barr
mbarr@criticaloutcome.com
519-858-5157
Critical Outcome Technologies Inc
Source:Eurekalert

Page: 1 2

Related biology news :

1. ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER
2. Gamma globulin effective in treating eye infections caused by adenoviruses
3. UC health news: molecular pathway may predict chemotherapy effectiveness
4. Socioeconomic position associated with effectiveness of HIV drugs
5. New nanoparticle vaccine is more effective but less expensive
6. MIT model could improve some drugs effectiveness
7. Trial seeks genetic fingerprint for predicting drug effectiveness
8. New hope for horse lovers as effective control for killer ragwort is proposed
9. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
10. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
11. Tamiflu effective for treatment and prevention of influenza in children 1 year and older
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... , May 25, 2015  Australia,s market for wearable ... although 2014 saw the advent of several trials and ... April 2015 is expected to ignite interest in wearables ... Australia . This in turn will ... and drive new partnerships amongst vendors and distributors. ...
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... key to the blinding effects of diabetic retinopathy is ... Georgia researchers said. Interleukin-6, known to contribute ... helps ignite inflammation of the retina, a first step ... blindness is working-age adults, MCG researchers reported online in ...
... of dollars each year on exotic smelling perfumes and lotions ... a new study in Psychological Science , a journal ... be the best way to capture a potential mate,s attention. ... habits: Animal studies have shown that male testosterone levels are ...
... Malaga have created the ,Inventory of Daily Stressors, a ... physical appearance, taking part in numerous extracurricular activities and ... that increase the risk of suffering from childhood stress. ... to assess daily stress amongst schoolchildren", Mara Victoria Trianes, ...
Cached Biology News:Discovery points toward anti-inflammation treatment for blinding disease 2A new method to measure childhood stress 2
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... on health care, Jack Uldrich has been selected ... in New York today. He will deliver his ... , Uldrich has delivered presentations to the American ... of Audiology and Neurology, Alcetel-Lucent/Verizon Forum on Wireless ...
(Date:6/1/2015)... and YONGIN, South Korea , June ... that Green Cross Biotherapeutics Inc. (GCBT) kicked off construction ... on the Montreal Technoparc,s Saint-Laurent Campus. The CA$315 million ... projects in Canada in the ... first intravenous immunoglobulin (IVIG) and albumin manufacturing plant in ...
(Date:6/1/2015)... , June 1, 2015 ... the fermentation of sugar or cellulose. Bio-alcohols are primarily ... be used as a replacement for gasoline in cars. ... at a CAGR of 9 percent over the period ... global bio-alcohols market can be segmented into five: transportation, ...
(Date:6/1/2015)... , June 1, 2015 ... announced the addition of the "Global PDT ... offering.        (Logo: ... Report 2014 is a professional and in-depth study ... , ,The report provides a basic overview of ...
Breaking Biology Technology:Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Global Bio-alcohols Market 2015-2019 2Global PDT Machine Industry Report 2014 2
... SAN FRANCISCO, Oct. 26 MedImmune, Inc. today ... Academy of Pediatrics (AAP),2007 National Conference & Exhibition, ... the prevention of respiratory syncytial virus (RSV), a,leading ... pleased to present data that provide key insights ...
... Healthcare Services,Inc. (NYSE: AHS ), the nation,s ... presentation on Tuesday, November 6, 2007 at 12:45 ... Annual Healthcare Conference,taking place at the Waldorf-Astoria Hotel ... ) Susan R. Nowakowski, President and Chief ...
... Required for Integra Merger, IRVINE, California, October 26 ... company, today reported that,less than 100,000 votes "FOR" are ... Holdings Corporation (NASDAQ: IART ),("Integra") pursuant to an ... 2007. Today,s special meeting of stockholders will remain ...
Cached Biology Technology:MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition 2MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition 3MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition 4MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition 5AMN Healthcare Services to Present at the CIBC World Markets 18th Annual Healthcare Conference 2IsoTis Reports Status of Merger Vote 2IsoTis Reports Status of Merger Vote 3IsoTis Reports Status of Merger Vote 4
XPC Immunogen: XPC (NP_004619, 141 a.a. ~ 251 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Biology Products: